Analytical Data
-
Gene name
Dlc2
- Application
-
Alternative Names
8 kDa dynein light chain b; C87222; cytoplasmic; Dlc2; DLC8b; DNCL1B; DYL2_HUMAN; Dynein light chain 2; Dynein light chain 2; cytoplasmic; Dynein light chain LC8 type 2; Dynein light chain LC8-type 2; Dynll2; MGC17810; MGC72334
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96FJ2
-
Expression Region
1-89aa
-
AA Sequence
MSDRKAVIKN ADMSEDMQQD AVDCATQAME KYNIEKDIAA YIKKEFDKKY NPTWHCIVGR NFGSYVTHET KHFIYFYLGQ VAILLFKSG
-
Molecular Weight
10.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DLC2 (Deleted in Liver Cancer 2) is a member of the Rho-GTPase-activating protein family, playing a critical role in regulating the actin cytoskeleton and signal transduction pathways involved in cell adhesion, migration, and proliferation. Its expression is often downregulated in various cancers, particularly liver cancer, suggesting that it might function as a tumor suppressor. Research into DLC2 has gained momentum due to its potential as a biomarker for cancer diagnosis and prognosis, as well as a target for therapeutic intervention. Understanding the molecular mechanisms underlying DLC2's activity, including its role in modulating Rho family GTPases and interacting with other cellular proteins, is essential to elucidate its functions in tumor suppression. The recombinant expression of DLC2 protein in various systems allows researchers to study its structure and function in detail, paving the way for the development of novel cancer treatments that leverage DLC2's regulatory properties. Furthermore, the ongoing exploration of DLC2’s interactions with signaling pathways involved in cell growth and motility is expected to provide insights into its potential roles in other diseases beyond cancer, thereby broadening the impact of DLC2 research in the field of cellular biology and therapeutics.
